BioNTech RNA Pharmaceuticals GmbH

The development of a ribonucleic acid (RNA)-based vaccine encoding a viral antigen that is translated by the vaccinated organism to protein to induce a protective immune response provides significant advantages over more conventional vaccine approaches.

At BioNTech, there are three different RNA platforms under development, namely non- modified uridine containing mRNA (uRNA), nucleoside modified mRNA (modRNA), and self-amplifying mRNA (saRNA).

BNT162 vaccine candidates based on the uRNA, modRNA, and saRNA formats are currently under investigation in three clinical trials with healthy adults (men and women) aged between 18 and 85 yrs.